Can cardiac rehabilitation improve LDL-cholesterol target attainment after acute coronary syndromes?

Piepoli MF Hoes AW Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315–2381.

Kotseva K Wood D De Bacquer D et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factors and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23: 636–648.

Park JE Chiang CE Munawar M et al. Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey. Eur J Prev Cardiol 2012; 19: 781–794.

Jernberg T Hasvold P Henriksson M et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 2015; 36: 1163–1170.

Ference BA Ginsberg HN Graham I et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38: 2459–2472.

Sabatine MS Giugliano RP Keech AC et al. Evolocumab and Clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713–1722.

Bohula EA Giugliano RP Cannon CP et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation 2015; 132: 1224–1233.

Sabatine MS De Ferrari GM Giugliano RP et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease. Circulation 2018; 138: 756–766.

Schwaab B Zeymer U Jannowitz C et al. Improvement of LDL cholesterol target acihievement rates through cardiac rehabilitation for patients after STEMI or NSTEMI in Germany: results of the PATIENT CARE registry. Eur J Prev Cardiol.. 2019; 26: 249–258.

Karoff M Held K Bjarnason-Wehrens B . Cardiac rehabilitation in Germany. Eur J Cardiovascul Prev Rehabil: official journal of the European Society of Cardiology, Working Groups on Epidemiology and Prevention and Cardiac Rehabilitation and Exercise Physiology 2007; 14: 18–27.

Kotseva K Wood D De Bacquer D et al. Determinants of participation and risk factor control according to attendance in cardiac rehabilitation programmes in coronary patients in Europe: EUROASPIRE IV survey. Eur J Prev Cardiol 2018; 25: 1242–1251.

Piepoli MF Corra U Benzer W et al. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovascul Prev Rehabil: official journal of the European Society of Cardiology, Working Groups on Epidemiology and Prevention and Cardiac Rehabilitation and Exercise Physiology 2010; 17: 1–17.

Bjarnason-Wehrens B McGee H Zwisler AD et al. Cardiac rehabilitation in Europe: results from the European Cardiac Rehabilitation Inventory Survey. Eur J Cardiovascul Prev Rehabil: official journal of the European Society of Cardiology, Working Groups on Epidemiology and Prevention and Cardiac Rehabilitation and Exercise Physiology 2010; 17: 410–418.

Anderson L Taylor RS . Cardiac rehabilitation for people with heart disease: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev 2014, pp. CD011273–CD011273.

Anderson L Sharp GA Norton RJ et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev 2017; 6: CD007130–CD007130.